Freenome Reports Third Quarter 2026 Financial Results
– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC – – Entered the public market and raised gross proceeds of $310 million – BRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ:FRNM), a personalized cancer detection company using an AI-driven multiomics platform to optimize single- and multi-cancer blood tests, today reported its financial results for the third quarter ended September 30, 2026, and provided guidance for 2026. Third Quarter Financial Highlights Total revenue was $183.5 million for the third quarter of 2026, driven primarily by $180.0 million recognized under our collaboration and license agree